Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphine or Fentanyl for Refractory Dyspnea in COPD
NCT03834363Phase 4Completed
- Start
- Nov 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fentanyl (transdermal patch + oral transmucosal lozenge) and morphine hydrochloride in chronic obstructive pulmonary disease (COPD) and Dyspnea (3 arms). Primary endpoint: Change in dyspnea sensation at 6 weeks. Started Nov 2019; status: completed.
02
Drugs
fentanyl (transdermal patch + oral transmucosal lozenge)morphine hydrochloride
03
Conditions
chronic obstructive pulmonary disease (COPD)Dyspnea
Beyond the preview
Go deeper on NCT03834363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834363.